NexImmune Sizes Up the Competition and Decides to Pause Myeloma T Cell Therapy Plans

Turns out NexImmune is not resistant to the tough competition in multiple myeloma. The company cited the competitive environment in the blood cancer space as reason for pausing enrollment on one of its two clinical candidates.